Scientific Session

2019 Program Summary

Now is an exciting time in the field of allergy and immunology!  This program is designed to allow attendees to continue exploring the Immunology Frontier.  Covered topics include current and emerging treatments in atopic dermatitis, translational targets for new asthma therapeutics and drug desensitization to chemotherapeutic agents and biologics.  In addition, recent advances in allergy diagnostic testing, an update on food allergy treatment as well as considerations in choosing a treatment for food allergy will also be presented.  



Program Objectives

At the conclusion of the conference, participants should be able to:

  • Discuss the efficacy of allergen immunotherapy (AIT)
  • Identify the optimal regimen and duration of AIT
  • Understand the safety of AIT
  • Discuss specific IgE testing
  • Discuss serum allergen-specific IgE tests:  difference amongst assays
  • Discuss component-resolved diagnostic testing - diagnostic utility I food allergy evaluation
  • Discuss component-resolved diagnostic testing - utility in alleged immunotherapy
  • Describe the role of filaggrin in AD
  • Identify the factors in the pathogenesis of AD
  • Evaluate the role of the microbiome in AD
  • Identify common pitfalls in the treatment of AD
  • Describe the rationale for an extended therapeutic ladder in refractory disease
  • Evaluate upcoming treatments and those that have no proven benefit
  • Learn methods for evaluation patient-reported outcome in antibody deficiency patients
  • Learn the present options in treating your patients and how to consider navigating them
  • Learn the current challenges diagnosis antibody deficiency disorders
  • Learn the spectrum and current context for primary immunodeficiencies
  • Learn the basis, rationale and best approach to applying genomic diagnosis in primary immunodeficiency
  • Define the term precision approaches to disease
  • Characterize the utility of biomarkers that can predict therapeutic responses to biologic therapies
  • Identify the value of pharmacodynamic biomarkers in determining target engagement and improvement in asthma care
  • Describe a new paradigm that explains irreversible airway obstruction and remodeling in severe asthma
  • Identify new approaches to maximize bronchodilation in asthma
  • Define the molecular mechanisms by which steroid act acutely to improve asthma outcomes

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership the American College of Allergy, Asthma and Immunology and the California Society for Allergy, Asthma and Immunology. The American College of Allergy, Asthma and Immunology is accredited by the ACCME to provide continuing medical education for physicians.

AMA Credit Designation Statement


Faculty Disclosure

Current guidelines state that participants in continuing medical education activities should be aware of any affiliation or financial interest that could affect the speaker’s presentation(s). Faculty members have completed conflict of interest declarations and those potential conflicts will be listed in the course syllabus.

Commercial Support

This activity is supported by commercial interests

Disclosure Policy

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all financial relationships with any commercial interest that have occurred within the past 12 months.  The ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

All identified conflicts of interest must be resolved and the educational content fully vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that the disclosures be provided to the learners prior to the start of the activity.  Individuals with no financial relationships to disclose must also inform the learners that no financial relationships exist.

Learners must also be informed with off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality.  It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations.

Expressed views do not necessarily reflect the opinions of the ACAAI.

Cultural and Linguistic Competency - California AB 1195

This activity is in compliance with California Assembly Bill 1195, which requires that all CME activities address cultural and linguistic competency in patient care delivery to meet the concerns of a diverse population through effective and appropriate professional development.

Satellite Activities

Industry led lectures and exhibits will be conducted as optional learning opportunities in conjunction with this event.  These optional activities are not certified for CME credit and are not planned or sanctioned by the American College of Allergy, Asthma and Immunology or CSAAI.

The Board of Directors of the California Society of Allergy, Asthma and Immunology (CSAAI) serves as the Planning Committee for the Educational Meeting. The Board includes the following physicians: Travis Miller, MD,  Sheila Bonilla, MD, Christina Schwindt, MD, Robert Eitches, MD, Madeleine Ramos, MD, Vinay Gowda, MD, Marilyn Li, MD, Raffi Tachdijian, MD and Vince Tubiolo, MD.


12:00 pm               Registration and Exhibits

1:50 pm                 Overview and Welcome & Pre-CME Survey

                                Robert Eitches, MD, President CSAAI

2:10 pm                 Food Allergy Treatment Update

               Matthew Greenhawt, MD

2:50 pm                 Mechanisms of Hypersensitivity Reactions Associated with Chemotherapeutic Agents and Biologicals             

                                David Sloane, MD

3:30 pm                 Panel Discussion/Q&A

4:15 pm                 Top Allergy Papers

                                Topic 1

                                Fellow #1 Name

                                Topic 2

                                Fellow #2 Name

5:00 pm                 Town Hall Meeting

                                Advocacy Council Update
                                J. Allen Meadows, MD, FACAAI

CSAAI Lobbyist – Kevin Pedrotti, Clear Advocacy

5:40 pm                 Faculty Panel Discussion/Q&A
6:00 pm                 Reception

7:00 am             Exhibits

8:00 am             Welcome & Overview
                            Madeleine Ramos, MD, Program Director

8:10 am             Atopic Dermatitis:  An Update on Pathophysiology    

                             Peter Lio, MD 

8:50 am             Precision Medicine in Severe Asthma

                             Reynold Panettieri, Jr., MD

9:30 am             Nuts and Bolts of Allergen Immunotherapy

                             Linda Cox, MD

10:10 am           Panel Discussion/Q&A

10:30 am           Break and Exhibits

10:50 am            Everything You Need to Know About Taking Care of Antibody Deficient Patients

                             Jordan Orange, MD, PhD                                  

11:30 am            Considerations in Choosing Treatment for Food Allergy      

                             Matthew Greenhawt, MD

12:10 pm            Atopic Dermatitis:  Current and Emerging Treatments

                             Peter Lio, MD

12:50 pm            Panel Discussion/Q&A

1:05 pm              Adjourn

6:30 am                 Annual Business Meeting Breakfast

7:00 am                 Break & Exhibits

8:00 am                 Overview

                               Marilyn Li, MD, Executive Director

8:10 am                 Update on Immunological and Diagnostic Advances in Primary Immunodeficiency

                               Jordan Orange, MD, PhD

8:50 am                 Allergy Diagnostic Testing

                               Linda Cox, MD

9:30 am                 Panel Discussion/Q&A

9:45 am                 Break & Exhibits

10:00 am               Drug Desensitizations to Chemotherapeutics and Biologicals:  The Brigham and Women’s Hospital Experience

                               David Sloane, MD

10:40 am              Translational Targets for New Asthma Therapeutics

                               Reynold Panettieri, Jr., MD                                                

11:20 am              Panel Discussion/Q&A

11:30 am              Closing Remarks

                              Robert Eitches, MD, President CSAAI

11:45 am             Adjourn


The CSAAI has assembled a world-class faculty for the 2018 Annual Meeting.

Linda Cox, MD

Session Topics:

Nuts and Bolts of Allergen Immunotherapy

Allergy Diagnostic Testing

Matthew Greenhawt, MD

Session Topics:

Food Allergy Treatment Update

Considerations in Choosing Treatment for Food Allergy

Peter Lio, MD

Session Topics:

Atopic Dermatitis: An Update on Pathophysiology

Atopic Dermatitis: Current and Emerging Treatments

Jordan S. Orange, MD, PhD

Session Topics:

Everything You Need to Know About Taking Care of Antibody Deficient Patients

Update on Immunological and Diagnostic Advances in Primary Immunodeficiencies

Reynold A. Panettieri, Jr., MD

Session Topics:

Precision Medicine in Severe Asthma

Translational Targets for New Asthma Therapeutics

David Edward Sloane, MD

Session Topics:

Mechanisms of Hypersensitivity Reactions Associated with Chemotherapeutic Agents and Biologicals

Drug Desensitization to Chemotherapeutic Agents and Biologicals: The Brigham and Women’s Hospital Experience